ClinicalTrials.gg
Active, not recruitingNCT07585877Updated Jul 13, 2026

Effect of Branched-Chain Amino Acid Supplementation on Myopia Progression

An interventional study of Branched-Chain Amino Acids (BCAA) Supplementation in Myopia Progressing and Myopia, sponsored by Zhongda Hospital. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 25 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-13.

Sponsored by Zhongda Hospital · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Jan 2026, registered Apr 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
104
Allocation
Randomized
Ages
18 Years to 25 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 222 studies in Myopia with a site in China — 80 open to participants now, 102 under way, 4 of them phase 3. Myopia · China.

Planned enrollment
101st of 155
104 · median 150
Started
2026
with 23 others
No phase
136 of 222
53 open now
Primary completion
2026-12
later than 49 of 101 live
Registered
204th of 222
by date

Among the 222 studies in Myopia with a site in China, this one is the 101st largest by planned enrollment of the 155 interventional ones that give a count, is one of 24 that started in 2026, is one of 136 with no phase, reaches primary completion later than 49 of the 101 other live ones, and was the 204th registered.

Myopia

1,166 studies on the registry are indexed under Myopia; 228 are open to participants now.

Browse Myopia studies →

Open to participants now

80 of the 222 studies in Myopia with a site in China are open now. Recruiting first, the newest first:

75 more — sign in →

All 80 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 124 Myopia studies recruiting now, 20 (16%) set no upper age limit and 103 (83%) stop at 75 or younger; 85 take children under 18; 53 take healthy volunteers.

This study: 18 Years to 25 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 222 studies in Myopia with a site in China, or all of them as a file.
02

Study summary

This study is a randomized controlled trial designed to evaluate whether branched-chain amino acid (BCAA) supplementation can help slow the progression of myopia in young adults.

Eligible participants will be randomly assigned to receive either BCAA supplementation combined with standard spectacle correction or standard spectacle correction with a matching placebo. The intervention period will last approximately six months.

Participants will undergo regular follow-up examinations, including measurements of visual acuity, refractive error, axial length, intraocular pressure, and other ocular parameters. Additional assessments such as ocular imaging (including OCTA), physical examinations, and blood tests will also be performed to evaluate eye health and metabolic indicators.

The main purpose of this study is to investigate whether BCAA supplementation can provide a safe and effective nutritional strategy to slow myopia progression and improve understanding of the relationship between amino acid metabolism and ocular growth.

03

Conditions studied

  • Myopia Progressing
  • Myopia

Browse trials for

Keywords

  • Myopia Progression
  • Branched-chain amino acids
  • Nutritional supplementation
  • Randomized controlled trial
  • Axial length
  • OCTA
04

Who can participate

Ages eligible
18 Years to 25 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy university students aged 18-25 years;
  2. Spherical equivalent refraction (for eyes without prior corneal refractive surgery): SE ≤ -0.50 D;
  3. Corrected visual acuity ≥ 0.8;
  4. Corneal curvature 40 D-46 D;
  5. Good compliance and ability to cooperate with follow-up and examinations;
  6. Willingness and ability to participate in this study and sign the form.

Exclusion criteria

Exclusion Criteria:

  1. Strabismus, amblyopia, or other pathological ocular changes;
  2. Systemic diseases affecting refractive development and allergic constitution, such as diabetes, metabolic syndrome, etc.;
  3. Active eye disease or history of ophthalmic surgery;
  4. Use of orthokeratology lenses or other myopia-control interventions within the past 6 months;
  5. Use of BCAA-related supplements within the past 6 months, or serum BCAA levels outside the reference range;
  6. Considered by the responsible physician to be unable to participate or unable to comply with the study requirements;
  7. Abnormal liver or kidney function.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
104 participants (estimated)

Study arms

  • Experimental
    BCAA Supplementation Group

    Participants receive daily oral branched-chain amino acid (BCAA) supplementation in addition to standard spectacle correction. The intervention is administered for approximately 6 months to evaluate its effect on myopia progression and ocular parameters.

    Dietary Supplement: Branched-Chain Amino Acids (BCAA) Supplementation

  • No intervention
    Control Group

    Participants in the control group will receive standard spectacle correction combined with a placebo identical in appearance to the BCAA supplement, without active BCAA ingredients. They will be followed for approximately 6 months to evaluate myopia progression and ocular outcomes.

Interventions

  • Dietary supplementAmino Acids, Branched-ChainStudies of Amino Acids, Branched-ChainAmino Acids, Branched-Chain pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants will receive oral branched-chain amino acids (BCAA), including leucine, isoleucine, and valine, as a dietary supplement in addition to standard spectacle correction. The intervention is administered daily for approximately 6 months. The supplement is a commercially available nutritional product obtained via cross-border e-commerce channels and is not intended as a therapeutic drug. The aim is to evaluate the effect of BCAA supplementation on myopia progression and ocular biometric parameters.

    Also known as: BCAA, Branched-chain amino acids

06

What researchers measure

Primary outcomes

  1. Change in axial length

    Axial length (AL) will be measured in both eyes using optical biometry at baseline, 3 months, and 6 months. The primary outcome is the change in axial length from baseline to 6 months, comparing the BCAA supplementation plus spectacle correction group with the spectacle correction only group.

    Time frame: Baseline to 6 months

  2. Change in spherical equivalent refractive error

    Cycloplegic spherical equivalent (SE) will be measured using autorefractometry under cycloplegia at baseline, 3 months, and 6 months. The primary outcome is the change in spherical equivalent refractive error from baseline to 6 months, comparing the BCAA supplementation group with the control group.

    Time frame: Baseline to 6 months

Secondary outcomes

  1. Superficial retinal vessel density

    Superficial retinal vessel density will be measured in both eyes using OCTA in foveal, parafoveal, and perifoveal regions. Sectoral measurements (temporal, superior, nasal, and inferior) will be obtained, and the final value will be calculated as the mean of all regions, reported as a percentage (%).

    Time frame: Baseline and 6 months

  2. Deep retinal vessel density

    Deep retinal vessel density will be measured in both eyes using OCTA across ETDRS regions. Sectoral measurements will be obtained, and the final value will be calculated as the mean of all regions, reported as a percentage (%).

    Time frame: Baseline and 6 months

  3. Choriocapillaris perfusion density

    Choriocapillaris perfusion will be measured in both eyes using OCTA across foveal, parafoveal, and perifoveal regions. Sectoral measurements will be obtained, and the final value will be calculated as the mean of all regions, reported as a percentage (%).

    Time frame: Baseline and 6 months

  4. Retinal perfusion density

    Retinal perfusion density will be measured in both eyes using OCTA across ETDRS regions, including full retinal perfusion and large-vessel-excluded perfusion. Sectoral measurements will be obtained, and the final value will be calculated as the mean of all regions, reported as a percentage (%).

    Time frame: Baseline and 6 months

  5. Family Ocular History

    Definition: Baseline refractive status of parents based on self-reported highest degree of myopia in either eye. Variable type: Categorical Measurement: Self-reported parental myopia status categorized as none, low (≤300°), moderate (300-600°), and high (≥600°).

    Time frame: Baseline

  6. Nutritional Supplement Use

    Definition: Baseline information on participants' use of any nutritional or dietary supplements. Variable type: Binary (Yes/No) Measurement: Self-reported use of dietary or nutritional supplements (Yes/No).

    Time frame: Baseline

  7. Protein Allergy History

    Definition: Baseline assessment of whether participants have a documented or self-reported history of protein allergy. Variable type: Binary (Yes/No) Measurement: Self-reported history of protein allergy (Yes/No).

    Time frame: Baseline

  8. Parental Education Level

    Parental education level at baseline, self-reported via structured questionnaire. Education levels are categorized as: primary school or below, junior/high school, university, and master's degree or above.Variable Type:Categorical

    Time frame: Baseline

  9. Daily Screen Time

    Average daily time spent using electronic devices (including television, mobile phone, computer, and projection screen) over the past week, assessed by questionnaire. Variable type: Categorical.

    Time frame: Baseline

  10. Eye Rest and Break Behavior

    Definition: Frequency of eye breaks during near work activities. Variable type: Categorical Measurement: Self-reported duration of continuous near work before rest (≤30 min, 30-60 min, 1-2 h, 2-3 h, ≥3 h).

    Time frame: Baseline

  11. Sleep Duration

    Definition: Average daily sleep duration over the past week. Variable type: Continuous Measurement: Self-reported average sleep time (hours and minutes per day).

    Time frame: Baseline

  12. Staple food intake frequency

    Frequency and quantity of staple food intake, including rice, wheat-based products, corn products, mixed beans, tubers, and fried flour-based foods, assessed using a semi-quantitative food frequency questionnaire.

    Time frame: Baseline

  13. Protein-rich food intake frequency

    Frequency and quantity of protein-rich food consumption, including soybeans and soy products, meat (pork, beef, lamb, poultry), aquatic products (fish, shrimp, shellfish), eggs, and dairy products, assessed using a semi-quantitative food frequency questionnaire.

    Time frame: Baseline

  14. Vegetable intake frequency

    Frequency and quantity of vegetable intake, including dark green vegetables, red/orange vegetables, purple vegetables, and light-colored vegetables, assessed using a semi-quantitative food frequency questionnaire.

    Time frame: Baseline

  15. Fruit intake frequency

    Frequency and quantity of fruit intake, including pome fruits, citrus fruits, stone fruits, berries, melons, and tropical fruits, assessed using a semi-quantitative food frequency questionnaire.

    Time frame: Baseline

  16. Dairy product intake frequency

    Frequency and quantity of dairy product consumption, including liquid milk, milk powder, and yogurt, assessed using a semi-quantitative food frequency questionnaire.

    Time frame: Baseline

  17. Snack and sugary food intake frequency

    Frequency and quantity of intake of snacks and sugary foods, including baked goods, nuts, processed snacks, sweets, and sugar-sweetened beverages, assessed using a semi-quantitative food frequency questionnaire.

    Time frame: Baseline

  18. Temporal Superior RNFL Thickness

    Peripapillary retinal nerve fiber layer (RNFL) thickness in the temporal superior (TU) sector measured by optical coherence tomography angiography (OCTA), reported in micrometers (µm).

    Time frame: Baseline and 6 months

  19. Superior Temporal RNFL Thickness

    Peripapillary RNFL thickness in the superior temporal (ST) sector measured by OCTA, reported in micrometers (µm).

    Time frame: Baseline and 6 months

  20. Superior Nasal RNFL Thickness

    Peripapillary RNFL thickness in the superior nasal (SN) sector measured by OCTA, reported in micrometers (µm).

    Time frame: Baseline and 6 months

  21. Nasal Superior RNFL Thickness

    Peripapillary RNFL thickness in the nasal superior (NU) sector measured by OCTA, reported in micrometers (µm).

    Time frame: Baseline and 6 months

  22. Nasal Inferior RNFL Thickness

    Peripapillary RNFL thickness in the nasal inferior (NL) sector measured by OCTA, reported in micrometers (µm).

    Time frame: Baseline and 6 months

  23. Inferior Nasal RNFL Thickness

    Peripapillary RNFL thickness in the inferior nasal (IN) sector measured by OCTA, reported in micrometers (µm).

    Time frame: Baseline and 6 months

  24. Inferior Temporal RNFL Thickness

    Peripapillary RNFL thickness in the inferior temporal (IT) sector measured by OCTA, reported in micrometers (µm).

    Time frame: Baseline and 6 months

  25. Temporal Inferior RNFL Thickness

    Peripapillary RNFL thickness in the temporal inferior (TL) sector measured by OCTA, reported in micrometers (µm).

    Time frame: Baseline and 6 months

  26. Global Average Peripapillary RNFL Thickness

    Global average peripapillary retinal nerve fiber layer (RNFL) thickness measured by optical coherence tomography angiography (OCTA), calculated as the mean thickness across all peripapillary regions, and reported in micrometers (µm).

    Time frame: Baseline and 6 months

  27. Optic Disc Area

    Optic disc area measured in both eyes using optical coherence tomography angiography (OCTA), reported in square millimeters (mm²).

    Time frame: Baseline and 6 months

  28. Neuroretinal Rim Area

    Neuroretinal rim area measured in both eyes using OCTA, reported in square millimeters (mm²).

    Time frame: Baseline and 6 months

  29. Optic Cup Volume

    Optic cup volume measured in both eyes using OCTA, reported in cubic millimeters (mm³).

    Time frame: Baseline and 6 months

  30. Cup-to-Disc Ratio

    Cup-to-disc ratio measured in both eyes using OCTA, defined as the ratio of optic cup diameter to optic disc diameter (unitless).

    Time frame: Baseline and 6 months

  31. Vertical Cup-to-Disc Ratio

    Vertical cup-to-disc ratio measured in both eyes using OCTA (unitless).

    Time frame: Baseline and 6 months

  32. Horizontal Cup-to-Disc Ratio

    Horizontal cup-to-disc ratio measured in both eyes using OCTA (unitless).

    Time frame: Baseline and 6 months

  33. Peripapillary Temporal Superior Sector Vessel Density

    Peripapillary microvascular vessel density in the temporal superior (TU) sector measured in both eyes using optical coherence tomography angiography (OCTA), reported as vessel density percentage (%).

    Time frame: Baseline and 6 months

  34. Peripapillary Superior Temporal Sector Vessel Density

    OCTA-derived vessel density in the superior temporal (ST) peripapillary sector in both eyes,reported as vessel density percentage (%).

    Time frame: Baseline and 6 months

  35. Peripapillary Superior Nasal Sector Vessel Density

    OCTA-derived vessel density in the superior nasal (SN) peripapillary sector in both eyes,reported as vessel density percentage (%).

    Time frame: Baseline and 6 months

  36. Peripapillary Nasal Superior Sector Vessel Density

    OCTA-derived vessel density in the nasal superior (NU) peripapillary sector in both eyes,reported as vessel density percentage (%).

    Time frame: Baseline and 6 months

  37. Peripapillary Nasal Inferior Sector Vessel Density

    OCTA-derived vessel density in the nasal inferior (NL) peripapillary sector in both eyes,

    Time frame: Baseline and 6 months

  38. Peripapillary Inferior Nasal Sector Vessel Density

    OCTA-derived vessel density in the inferior nasal (IN) peripapillary sector in both eyes,reported as vessel density percentage (%).

    Time frame: Baseline and 6 months

  39. Peripapillary Inferior Temporal Sector Vessel Density

    OCTA-derived vessel density in the inferior temporal (IT) peripapillary sector in both eyes,reported as vessel density percentage (%).

    Time frame: Baseline and 6 months

  40. Peripapillary Temporal Inferior Sector Vessel Density

    OCTA-derived vessel density in the temporal inferior (TL) peripapillary sector in both eyes,reported as vessel density percentage (%).

    Time frame: Baseline and 6 months

  41. Global Peripapillary Vessel Density

    Mean peripapillary microvascular vessel density calculated across all peripapillary sectors in both eyes using OCTA,reported as vessel density percentage (%).

    Time frame: Baseline and 6 months

  42. Full Macular Retinal Thickness

    Full retinal thickness in the macular region measured in both eyes using optical coherence tomography angiography (OCTA), including foveal, parafoveal, and perifoveal regions across temporal, superior, nasal, and inferior sectors.

    Time frame: Baseline and 6 months

  43. Macular Inner Retinal Layer Thickness

    Inner retinal layer thickness in the macular region measured in both eyes using OCTA, assessed at foveal, parafoveal, and perifoveal regions across four quadrants (temporal, superior, nasal, inferior).

    Time frame: Baseline and 6 months

  44. Macular Outer Retinal Layer Thickness

    Outer retinal layer thickness in the macular region measured in both eyes using OCTA, including foveal, parafoveal, and perifoveal regions across temporal, superior, nasal, and inferior sectors.

    Time frame: Baseline and 6 months

  45. Foveal Avascular Zone Area

    Foveal avascular zone (FAZ) area measured in both eyes using optical coherence tomography angiography (OCTA).

    Time frame: Baseline and 6 months

  46. FAZ-300 Superficial Capillary Plexus Perfusion Density

    Perfusion density in a 300 μm annular region surrounding the FAZ in the superficial capillary plexus measured using OCTA.

    Time frame: Baseline and 6 months

  47. FAZ-300 Deep Capillary Plexus Perfusion Density

    Perfusion density in a 300 μm annular region surrounding the FAZ in the deep capillary plexus measured using OCTA.

    Time frame: Baseline and 6 months

  48. FAZ-300 Full Retinal Perfusion Density

    Perfusion density in a 300 μm annular region surrounding the FAZ across full retinal layers measured using OCTA.

    Time frame: Baseline and 6 months

  49. Alanine Aminotransferase (ALT)

    Serum alanine aminotransferase (ALT) measured in fasting venous blood using standard laboratory methods. Values will be analyzed as continuous variables and categorized as normal or abnormal based on clinical reference ranges.

    Time frame: Baseline and 6 months

  50. Aspartate Aminotransferase (AST)

    Serum AST measured using standard laboratory methods in fasting venous blood. Values will be analyzed as continuous variables and categorized as normal or abnormal based on clinical reference ranges.

    Time frame: Baseline and 6 months

  51. Total Bilirubin (TBil)

    Serum total bilirubin measured in fasting venous blood. Values will be analyzed as continuous variables and categorized as normal or abnormal based on clinical reference ranges.

    Time frame: Baseline and 6 months

  52. Serum Creatinine (Scr)

    Serum creatinine measured in fasting venous blood using standard laboratory methods. Values will be analyzed as continuous variables and categorized as normal or abnormal based on clinical reference ranges.

    Time frame: Baseline and 6 months

  53. Blood Urea Nitrogen (BUN)

    BUN measured in fasting venous blood using standard laboratory methods. Values will be analyzed as continuous variables and categorized as normal or abnormal based on clinical reference ranges.

    Time frame: Baseline and 6 months

  54. Uric Acid (UA)

    Serum uric acid measured in fasting venous blood using standard laboratory methods. Values will be analyzed as continuous variables and categorized as normal or abnormal based on clinical reference ranges.

    Time frame: Baseline and 6 months

  55. Fasting Plasma Glucose (FPG)

    Fasting plasma glucose measured in fasting venous blood using standard laboratory methods. Values will be analyzed as continuous variables and categorized as normal or abnormal based on clinical reference ranges.

    Time frame: Baseline and 6 months

  56. Total Cholesterol (TC)

    Serum total cholesterol measured in fasting venous blood using standard laboratory methods. Values will be analyzed as continuous variables and categorized as normal or abnormal based on clinical reference ranges.

    Time frame: Baseline and 6 months

  57. Triglycerides (TG)

    Serum triglycerides measured in fasting venous blood using standard laboratory methods. Values will be analyzed as continuous variables and categorized as normal or abnormal based on clinical reference ranges.

    Time frame: Baseline and 6 months

  58. High-Density Lipoprotein Cholesterol (HDL-C)

    HDL cholesterol measured in fasting venous blood using standard laboratory methods. Values will be analyzed as continuous variables and categorized as normal or abnormal based on clinical reference ranges.

    Time frame: Baseline and 6 months

  59. Low-Density Lipoprotein Cholesterol (LDL-C)

    LDL cholesterol measured in fasting venous blood using standard laboratory methods. Values will be analyzed as continuous variables and categorized as normal or abnormal based on clinical reference ranges.

    Time frame: Baseline and 6 months

  60. Sex of Participants

    Participant sex recorded at baseline using structured questionnaire.

    Time frame: Baseline

  61. Age of Participants

    Age calculated from date of birth at baseline using structured questionnaire.

    Time frame: Baseline

  62. Ethnicity of Participants

    Ethnicity recorded at baseline using structured questionnaire.

    Time frame: Baseline

  63. Body Mass Index (BMI)

    BMI calculated from weight and height measured at baseline.Units:kg/m², Type:Continuous

    Time frame: Baseline

  64. Household Residence

    Household residence (urban/rural) recorded at baseline using structured questionnaire.Type:Categorical

    Time frame: Baseline

  65. Annual Household Income

    Annual household income recorded at baseline using structured questionnaire.Type : categorical

    Time frame: Baseline

  66. Study Pressure Level

    Self-reported level of study pressure and workload, assessed by questionnaire with four levels ranging from low to high. Variable type: Categorical.

    Time frame: Baseline

  67. Unhealthy Visual Habits

    Presence of unhealthy visual habits (e.g., reading under strong sunlight, using screens in dark environments, improper posture during near work), assessed by multiple-choice questionnaire. Variable type: Categorical (multiple response).

    Time frame: Baseline

  68. Lighting Conditions During Nighttime Near Work

    Lighting conditions used during near-work activities after dark (e.g., desk lamp, ceiling light), assessed by questionnaire. Variable type: Categorical.

    Time frame: Baseline

  69. Moderate-to-Vigorous Physical Activity Duration

    Average daily duration of moderate-to-vigorous physical activity (e.g., brisk walking, running, jumping rope, cycling) over the past week, assessed by questionnaire. Variable type: Categorical.

    Time frame: Baseline

07

Study locations

1 site
  • School of Public Health, Southeast University
    Nanjing, Jiangsu 210096, China
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Dec 2026, 11 months after the start.

Of 202 non-industry interventional studies with no phase under Myopia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 44. This study's planned 11 months is below that.

Counting every sponsor, half of 438 studies reached it within 14 months; a quarter within 3 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2026
First posted
May 14, 2026
StartActual
Jan 5, 2026
Primary completionEst.
Dec 30, 2026
CompletionEst.
Jan 30, 2027
Last update
Jul 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07585877
Lead sponsor
Zhongda Hospital
Responsible party
Weina Liu (Associate Professor, Southeast University, China) — Principal investigator
First posted
May 14, 2026
Start date
Jan 5, 2026
Primary completion
Dec 30, 2026 (estimated)
Completion
Jan 30, 2027 (estimated)
Last update
Jul 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Amino Acids, Branched-Chain

Start the discussion